×
About 1,013 results

ALLMedicine™ Alpha-1 Antitrypsin Deficiency Center

Research & Reviews  314 results

Occupational and environmental exposures in the Genomic Research in Alpha-1 Antitrypsin...
https://doi.org/10.1016/j.rmed.2022.106923
Respiratory Medicine; Ryan SM, Mroz MM et. al.

Aug 7th, 2022 - Sarcoidosis is a granulomatous disorder thought to be caused by exposures in genetically susceptible individuals. This study investigated whether specific exposures were associated with different sarcoidosis phenotypes. Extensive demographic, occu...

Respreeza® Self-administration and Learning Program (AmAREtTI Study)
https://clinicaltrials.gov/ct2/show/NCT04262284

Aug 2nd, 2022 - According to the Respreeza® Summary of Product Characteristics, the initial infusions must be administered under the supervision of a health professional experienced in the treatment of alpha-1 antitrypsin deficiency, although subsequent infusions...

Alpha-1 Antitrypsin Deficiency Liver Disease.
https://doi.org/10.1016/j.cld.2022.03.004
Clinics in Liver Disease; Suri A, Patel D et. al.

Jul 23rd, 2022 - Liver disease in homozygous ZZ alpha-1 antitrypsin (AAT) deficiency occurs due to the accumulation of large quantities of AAT mutant Z protein polymers in the liver. The mutant Z protein folds improperly during biogenesis and is retained within th...

Disease progression in patients with PI*ZZ alpha-1 antitrypsin deficiency.
https://doi.org/10.1097/MEG.0000000000002395
European Journal of Gastroenterology & Hepatology; Shen K, Lyu R et. al.

Jul 9th, 2022 - Alpha-1 antitrypsin deficiency (AATD) is an uncommon but underdiagnosed cause of cirrhosis and lacks medical treatment options. It is important to recognize risk factors that contribute to disease progression and liver transplantation. We aimed to...

Optimization of Donor-Recipient Matching in Lung Transplantation
https://clinicaltrials.gov/ct2/show/NCT05195853

Jun 30th, 2022 - Lung transplantation is the curative treatment for end-stage respiratory failure involving highly selected patients. In 2018, the International Transplant Registry counts 69200 lung transplants among 260 transplant centers. Between 2010 and June 2...

see more →

Guidelines  3 results

Non-invasive diagnosis and follow-up of rare genetic liver diseases.
https://doi.org/10.1016/j.clinre.2021.101768
Clinics and Research in Hepatology and Gastroenterology; Sobesky R, Guillaud O et. al.

Aug 1st, 2021 - Rare genetic liver diseases can result in multi-systemic damage, which may compromise the patient's prognosis. Wilson's disease and alpha-1 antitrypsin deficiency must be investigated in any patient with unexplained liver disease. Cystic fibrosis ...

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373286
Canadian Respiratory Journal; Marciniuk DD, Hernandez P et. al.

Apr 27th, 2012 - Alpha-1 antitrypsin (A1AT) functions primarily to inhibit neutrophil elastase, and deficiency predisposes individuals to the development of chronic obstructive pulmonary disease (COPD). Severe A1AT deficiency occurs in one in 5000 to one in 5500 o...

see more →

Clinicaltrials.gov  34 results

Respreeza® Self-administration and Learning Program (AmAREtTI Study)
https://clinicaltrials.gov/ct2/show/NCT04262284

Aug 2nd, 2022 - According to the Respreeza® Summary of Product Characteristics, the initial infusions must be administered under the supervision of a health professional experienced in the treatment of alpha-1 antitrypsin deficiency, although subsequent infusions...

Optimization of Donor-Recipient Matching in Lung Transplantation
https://clinicaltrials.gov/ct2/show/NCT05195853

Jun 30th, 2022 - Lung transplantation is the curative treatment for end-stage respiratory failure involving highly selected patients. In 2018, the International Transplant Registry counts 69200 lung transplants among 260 transplant centers. Between 2010 and June 2...

An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)
https://clinicaltrials.gov/ct2/show/NCT05146882

Jun 27th, 2022 - This is a Phase 2, multicenter, open-label extension of Study DCR-A1AT-201, designed to evaluate the long-term safety and further characterize the pharmacodynamics (PD) of belcesiran in adult patients with PiZZ AATLD.

Study of ARO-AAT in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
https://clinicaltrials.gov/ct2/show/NCT03946449

May 4th, 2022 - Participants will be enrolled to receive multiple subcutaneous injections of ARO-AAT. All eligible participants will require a pre-dose biopsy completed as part of the study within the screening window. All participants will undergo an End of Stud...

Longitudinal Study of Mitochondrial Hepatopathies
https://clinicaltrials.gov/ct2/show/NCT01148550

Apr 22nd, 2022 - This study will be conducted as part of the NIH-supported Childhood Liver Disease Research and Education Network (ChiLDREN). ChiLDREN is investigating rare cholestatic liver diseases of childhood: alpha-1 antitrypsin deficiency (A1AT), Alagille's ...

see more →

News  46 results

COPD Screening for Asymptomatic Adults? USPSTF Weighs In, Again
https://www.medscape.com/viewarticle/973787

May 11th, 2022 - Screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults has no net benefit, according to a U.S. Preventive Services Task Force (USPSTF) reassessment of its 2016 screening recommendations. The new recommendation is in line...

COPD screening for asymptomatic adults? USPSTF weighs in, again
https://www.mdedge.com/chestphysician/article/254452/copd/copd-screening-asymptomatic-adults-uspstf-weighs-again
Mark S. Lesney, PhD, MDedge News

May 10th, 2022 - Screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults has no net benefit, according to a U. S.

Deja Vu All Over Again; Delay of Game: NFL Vaccine Pushback; Third FDA Advisor Quits
https://www.medpagetoday.com/infectiousdisease/covid19/93049

Jun 11th, 2021 - Note that some links may require registration or subscription. Here we go again. As cruise lines struggle to recover from COVID-19, two passengers aboard a Royal Caribbean ship tested positive for coronavirus; all crew and passengers over 16 were ...

HCC Etiologic Risk Factors and Global Prevalence
https://www.onclive.com/view/hcc-etiologic-risk-factors-and-global-prevalence

Apr 2nd, 2021 - Minsig Choi, MD: What are the etiology risk factors in the development of hepatocellular cancer? We all know that hepatocellular cancer or liver cancer is caused by a chronic irritation or inflammations. Usually the most common causes of this irri...

Point Mutation May Help Explain Different National COVID-19 Death Rates
https://www.medscape.com/viewarticle/938411

Oct 2nd, 2020 - NEW YORK (Reuters Health) - Ethnic differences in the frequencies of alpha-1 antitrypsin deficiency alleles might contribute to national differences in COVID-19 fatality rates, researchers report. "It was interesting to see how one point mutation ...

see more →

Patient Education  8 results see all →